Bristol-myers Squibb Compnay

Innate Tumor Immunity, Inc.

Lantheus Medical Imaging, Inc.

Matthias Broekema

Christine M Tarby

Ashvinikumar V Gavai

Derek J Norris

Ying Wang

Sanjeev Gangwar

Qian Zhang

Dean A Wacker

Chunjian Liu

Simon P Robinson

Scott Hunter Watterson

Heike S Radeke

David S Casebier

John S Tokarski

Thomas David Harris

Steven P Seitz

Prasanna Sivaprakasam

Yong Zhang

Ming Yu

Liqi He

Yam B Poudel

Gang Wu

Ajay Purohit

Richard R Cesati

Daniel O'Malley

David C Onthank

Naidu S Chowdari

Patrice Gill

Carol Hui Hu

Hua Gong

Wei Wang

Vijay T Ahuja

Matthew Cox

Jianxin Feng

Joseph E Carpenter

Michael Wichroski

Thomas D Harris

Julian C Lo

Mohini Rajasagi

Chunjian C Liu

The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Uracil derivatives as Mer-AXL inhibitors

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Alkene compounds as farnesoid x receptor modulators

Novel compounds of structure Formula I: (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds. 

Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators

Growing community of inventors

New Hope, PA, United States of America

Matthias Broekema